Read by QxMD icon Read

Ovarian , endometrial , cervical , vulvar , cancer ,

Murat Gultekin, Irem Kucukyildiz, Mujdegul Zayifoglu Karaca, Selin Dundar, Guledal Boztas, Semra Hatice Turan, Ezgi Hacikamiloglu, Bekir Keskinkilic
OBJECTIVE: The aim of this study was to evaluate nationwide gynecological cancer trends in Turkey. METHODS: National cancer registry data (2009-2013) of Turkish Ministry of Health were evaluated. Ovarian, cervical, endometrial, vulvar, vaginal, and tubal cancers are evaluated with respect to age of diagnosis, incidence rates within years, stage, histological distributions, and mortality rates. Data were collected from active cancer registry centers, which increased from 23% in 2009 to 47...
October 2017: International Journal of Gynecological Cancer
Christine Garcia, Carolyn Lefkowits, Elizabeth Pelkofski, Leslie Blackhall, Linda R Duska
OBJECTIVE: To characterize risk for opioid misuse among gynecologic oncology patients. METHODS: The Opioid Risk Tool (ORT), a validated screen for opioid misuse risk, was administered to a convenience sample of patients with gynecologic cancer receiving opioid prescriptions in gynecologic oncology or palliative care clinics from January 2012-June 2016. Demographic and clinical information was abstracted on chart review. The primary outcome was ORT risk level (low vs...
August 11, 2017: Gynecologic Oncology
Nicoletta Biglia, Valentina Zanfagnin, Alberto Daniele, Elisabetta Robba, Valentina E Bounous
Lower body lymphedema is a chronic condition and a significant cause of morbidity following treatment of gynecologic cancer that strongly impacts patients' quality of life (QoL). Most studies on secondary lymphedema have been performed on the upper limb after breast cancer treatment and much less is known about lower body lymphedema after gynecologic malignancies. This review focuses on secondary lymphedema due to gynecologic cancer treatment, analyzing its incidence in the different types of gynecologic cancer, diagnosis, risk factors, impact on QoL and treatment...
August 2017: Anticancer Research
Murat Gultekin, Irem Kucukyildiz, Mujdegul Zayifoglu Karaca, Selin Dundar, Guledal Boztas, Semra Hatice Turan, Ezgi Hacikamiloglu, Bekir Keskinkilic
OBJECTIVE: The aim of this study was to evaluate nationwide gynecological cancer trends in Turkey. METHODS: National cancer registry data (2009-2013) of Turkish Ministry of Health were evaluated. Ovarian, cervical, endometrial, vulvar, vaginal, and tubal cancers are evaluated with respect to age of diagnosis, incidence rates within years, stage, histological distributions, and mortality rates. Data were collected from active cancer registry centers, which increased from 23% in 2009 to 47...
September 2017: International Journal of Gynecological Cancer
Elahe Seyed Hosseini, Matthieu Meryet-Figuiere, Hamed Sabzalipoor, Hamed Haddad Kashani, Hossein Nikzad, Zatollah Asemi
Cancers of the female reproductive system include ovarian, uterine, vaginal, cervical and vulvar cancers, which are termed gynecologic cancer. The emergence of long noncoding RNAs (lncRNAs), which are believed to play a crucial role in several different biological processes, has made the regulation of gene expression more complex. Although the function of lncRNAs is still rather elusive, their broad involvement in the initiation and progression of various cancers is clear. They are also involved in the pathogenesis of cancers of the female reproductive system...
June 21, 2017: Molecular Cancer
Marcela G Del Carmen, Laurel W Rice
OBJECTIVE: Women with gynecologic malignancies will be cured or may become long-term survivors. Management of menopausal symptoms is important in addressing their quality of life. We review the benefit and safety of hormone therapy use in these patients. METHODS: MEDLINE was searched for studies on menopause management published in English through December of 2016. RESULTS: Available data suggest that short-term use of hormone therapy in gynecologic cancer patients who do not have an estrogen-dependent malignancy do not adversely impact oncologic outcome and results in improvement of menopausal vasomotor and genitourinary symptoms...
August 2017: Gynecologic Oncology
Nadav Michaan, Dan Grisaru
Treatment of gynecological malignancies can cause an abrupt onset of menopausal symptoms along with associated long term morbidity. Hormone replacement therapy (HRT) is the most effective treatment to alleviate these symptoms but the safety of HRT among gynecologic oncology patients remains controversial. We conducted a review of the published literature on the risk of recurrent disease among gynecologic cancer patients using HRT. Our research revealed a shortage of prospective, randomized trials on this important subject...
March 2017: Harefuah
Rüdiger Klapdor, Hermann Hertel, Philipp Soergel, Matthias Jentschke, Peter Hillemanns
PURPOSE: Evaluating the application of the sentinel lymph node dissection (SLND) in gynecological cancers among German hospitals. METHODS: Between March and June 2016 an online questionnaire on SLND in gynecologic cancers was sent by email to all German gynecologic cancer centers, all university hospitals and general hospitals for which an email address was available. The survey contained 61 questions regarding the SLND in vulvar, cervical, endometrial and ovarian cancer...
March 2017: Archives of Gynecology and Obstetrics
Dong Hoon Suh, Miseon Kim, Hak Jae Kim, Kyung Hun Lee, Jae Weon Kim
In 2015, fourteen topics were selected as major research advances in gynecologic oncology. For ovarian cancer, high-level evidence for annual screening with multimodal strategy which could reduce ovarian cancer deaths was reported. The best preventive strategies with current status of evidence level were also summarized. Final report of chemotherapy or upfront surgery (CHORUS) trial of neoadjuvant chemotherapy in advanced stage ovarian cancer and individualized therapy based on gene characteristics followed...
November 2016: Journal of Gynecologic Oncology
Joseph Menczer
PURPOSE: Platelets have multiple functions and they also play an important role in malignancies. Elevated platelet count and thrombocytosis at the time of diagnosis in patients with many solid tumors correlates with prognosis and is associated with poor survival. The aim of the following report is to review the literature concerning elevated platelet count and thrombocytosis in gynecologic malignancies. METHOD: A PubMed search of all English literature peer-reviewed publications was performed containing the terms elevated platelet count or thrombocytosis and vulvar cancer, cervical cancer, endometrial cancer, and ovarian cancer...
January 2017: Archives of Gynecology and Obstetrics
Jorge Daniel Oldan, Parth S Patel
IMPORTANCE: Positron emission tomography/Computed tomography(PET/CT) is widely used for gynecologic cancers. OBJECTIVE: To determine when PET/CT should be used for gynecologic cancers. EVIDENCE ACQUISITION: PubMed was reviewed for articles on PET/CT of all gynecologic cancers. National Comprehensive Cancer Network, Society of Gynecologic Oncology, and American College of Radiology guidelines were reviewed. RESULTS: Whole-body PET/CT is useful for (1) initial staging of cervical and endometrial cancer, posttherapy assessment, radiation therapy planning, and posttreatment surveillance of cervical cancer, and (2) assessment of recurrence of cervical, endometrial, or ovarian cancer in the presence of symptoms...
September 2016: Obstetrical & Gynecological Survey
Tarra Evans, Ursula Matulonis
Next-generation sequencing (NGS) has risen to the forefront of tumor analysis and has enabled unprecedented advances in the molecular profiling of solid tumors. Through massively parallel sequencing, previously unrecognized genomic alterations have been unveiled in many malignancies, including gynecologic cancers, thus expanding the potential repertoire for the use of targeted therapies. NGS has expanded the understanding of the genomic foundation of gynecologic malignancies and has allowed identification of germline and somatic mutations associated with cancer development, enabled tumor reclassification, and helped determine mechanisms of treatment resistance...
September 2016: Journal of the National Comprehensive Cancer Network: JNCCN
Alla G Wernicke, Sae Kim, He Liu, Neil H Bander, Edyta C Pirog
The goal of the study was to examine expression of prostate-specific membrane antigen (PSMA) in neovasculature of gynecologic cancers, as PSMA-targeted therapy has showed a promise in treatment of advanced carcinomas. The study included cervical carcinoma (n=28), vulvar carcinoma (n=20), endometrial carcinoma (n=23), primary ovarian carcinoma (n=21), metastatic ovarian carcinoma (n=25), and normal cervix (n=12) as negative control. All cases were immunostained using anti-CD31 antibody to delineate capillary endothelial cells...
February 9, 2016: Applied Immunohistochemistry & Molecular Morphology: AIMM
Saptarshi Ghosh, Pamidimukkala Bramhananda Rao
INTRODUCTION: Osseous metastasis in gynaecological epithelial tumours is an extremely rare phenomenon occurring in less than 1% of these cancers. AIM: To analyse the clinical characteristics and prognosis in patients with gynaecological epithelial cancers with bone metastases. MATERIALS AND METHODS: This was a single institutional retrospective study done with the data available from January 2008 to January 2015. Out of 1686 patients with epithelial gynaecological malignancies there were a total 18 (1...
December 2015: Journal of Clinical and Diagnostic Research: JCDR
Shannon N Westin, Charlotte C Sun, Celestine S Tung, Robin A Lacour, Larissa A Meyer, Diana L Urbauer, Michael M Frumovitz, Karen H Lu, Diane C Bodurka
PURPOSE: While overall survival from gynecologic malignancies has greatly improved over the last three decades, required treatments can lead to multiple health issues for survivors. Our objective was to identify health concerns that gynecologic cancer survivors face. METHODS: A systematic, stratified sample of women with gynecologic malignancies was surveyed for 18 health issues occurring before, during, or after treatment. The impact of clinical features and treatment modality on health issues was assessed through multivariate logistic regression models...
April 2016: Journal of Cancer Survivorship: Research and Practice
Marcelo A Queiroz, Rahel A Kubik-Huch, Nik Hauser, Bianka Freiwald-Chilla, Gustav von Schulthess, Johannes M Froehlich, Patrick Veit-Haibach
PURPOSE: To compare the diagnostic accuracy of PET/MRI and PET/CT for staging and re-staging advanced gynaecological cancer patients as well as identify the potential benefits of each method in such a population. MATERIAL AND METHODS: Twenty-six patients with suspicious or proven advanced gynaecological cancer (12 ovarian, seven cervical, one vulvar and four endometrial tumours, one uterine metastasis, and one primary peritoneal cancer) underwent whole-body imaging with a sequential trimodality PET/CT/MR system...
August 2015: European Radiology
Christhardt Köhler, Sarah Kyeyamwa, Simone Marnitz, Audrey Tsunoda, Filiberto Vercelino, Achim Schneider, Giovanni Favero
INTRODUCTION: Pelvic ± para-aortic lymphadenectomy (LAE) is an essential element of staging and treatment of different gynecologic malignancies. However, LAE can induce asymptomatic and symptomatic pelvic lymphoceles (LCs) in a considerable percentage of patients. Therapy of symptomatic LCs may cause additional morbidity. The best strategy to reduce the rate of LCs has not established yet. MATERIALS AND METHODS: Between January 2011 and May 2012, transperitoneal laparoscopic pelvic ± para-aortic LAE was performed at the Department of Gynecology at Charité University Hospital Berlin in 238 patients with cervical, endometrial, ovarian, or groin-positive vulvar cancer...
March 2015: Journal of Minimally Invasive Gynecology
Jean-Baptiste Guy, Jane-Chloé Trone, François Casteillo, Fabien Forest, Cécile Pacaut, Coralie Moncharmont, Sophie Espenel, Alexis Vallard, Julien Langrand Escure, Olivier Collard, Michel Peoc'h, Nicolas Magné
Carcinosarcoma, also known as mixed mesodermal tumor or malignant mixed Mullerian tumor (MMMT) is a pathological entity combining a sarcomatous and a carcinomatous component. Found in thoracic, digestive, genitourinary, liver or skin locations, the most common location is the female genital tract. In gynecological tumors, carcinosarcoma accounts for about 2-5% of endometrial cancers, and 1% of ovarian cancers. To date, there is no consensus on the therapeutic strategy. It relies mostly on maximum cytoreductive surgery...
July 2014: Bulletin du Cancer
Alireza Mehrtash, Antonio Damato, Guillaume Pernelle, Lauren Barber, Nabgha Farhat, Akila Viswanathan, Robert Cormack, Tina Kapur
Gynecologic malignancies, including cervical, endometrial, ovarian, vaginal and vulvar cancers, cause significant mortality in women worldwide. The standard care for many primary and recurrent gynecologic cancers consists of chemoradiation followed by brachytherapy. In high dose rate (HDR) brachytherapy, intracavitary applicators and/or interstitial needles are placed directly inside the cancerous tissue so as to provide catheters to deliver high doses of radiation. Although technology for the navigation of catheters and needles is well developed for procedures such as prostate biopsy, brain biopsy, and cardiac ablation, it is notably lacking for gynecologic HDR brachytherapy...
March 12, 2014: Proceedings—Society of Photo-Optical Instrumentation Engineers
Chyong-Huey Lai, Gigin Lin, Tzu-Chen Yen, Feng-Yuan Liu
OBJECTIVES: The purpose of this review is to summarize literature pertaining to clinical roles of positron emission tomography (PET) or integrated PET and computed tomography (PET/CT) scans, magnetic resonance imaging (MRI) and emerging techniques of these two molecular imaging tools for gynecologic malignancies. METHODS: PubMed and MEDLINE databases search for articles published before June 2014 was performed. Only English-language articles were considered. Search terms included "cervical cancer", "endometrial cancer", "uterine cancer", "uterine sarcoma", "ovarian cancer" and "vulvar cancer", in association with "FDG", "PET", "PET/CT", "MRI", "PET/MR", "diffusion", "spectroscopy" and "clinical trial"...
October 2014: Gynecologic Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"